Background:

BGP Technologies is a fictitious biotech company that provides pharmaceutical consulting, custom drug manufacturing, and a line of consumer medical devices and generic drugs to customers worldwide. It has consulting offices in most of the major cities in the world, with manufacturing plants in the United States, China, and Mexico. Recently, the worldwide financial slump has put the company in a difficult position. Before the downturn, the company could absorb the litigation costs associated with its operations as part of the normal cost of doing business; now it can no longer afford to do so. BGP Technologies wants to implement whatever actions it can to avoid or at least minimize some of the legal pitfalls facing it in its worldwide operations

Problem:

Conduct research on what companies (BGP)can do to minimize legal risks associated with sales contracts, product liability, and performance on sales contracts